Human cellular prion protein (PrP C ) is involved in several neurodegenerative disorders; however, its normal function is unknown. We report here that a synthetic peptide corresponding to the four-octarepeat sequence of the PrP C (PrP 59-91 ) protects hippocampal neurons against copper neurotoxic effects in vivo. Using a rat bilateral intrahippocampal injection model, we found that PrP 59-91 protects against copper-induced neurotoxicity, including a recovery in spatial learning performance and a reduced neuronal cell loss and astrogliosis. Previous studies from our laboratory indicated that a tryptophan (Trp) residue plays a key role in the reduction of copper(II) to copper(I); therefore several PrP 59-91 fragments lacking histidine (His) and Trp residues were tested for their capacity to protect from copper toxicity. A PrP 59-91 peptide lacking His residue shows as much neuroprotection as the native peptide; however, PrP 59-91 without Trp residues only partially protected against copper toxicity. The neuroprotective effect not only occurs with PrP 59-91 , in fact a full neuroprotection was also observed using just one octamer of the N-terminal region of prion protein. We conclude that the N-terminal tandem octarepeat of the human PrP C protects neurons against copper toxicity by a differential contribution of the binding (His) and reducing (Trp) copper activities of PrP 59-91 . Our results are consistent with the idea that PrP C function is related to copper homeostasis.
Introduction
Prion cellular protein (PrP C ) has become one of the most intriguing proteins involved in several animal and human spongiform encephalopathies, including familial Creutzfeldt-Jakob and 'mad cow disease'. The normal function of PrP C is still unresolved, although it is known that PrP C null mice show an impaired long-term potentiation, which relates to PrP with a normal synaptic function. 1 Besides, PrP C has been involved in the regulation of sleep and circadian rhythms. 2, 3 However, growing evidence suggests that prion protein is involved in the metabolism of copper, [4] [5] [6] being considered a copperbinding protein. Copper is essential for the functioning of numerous enzymes expressed in the brain, including dopamine-b-hydroxylase, 7 cytochrome c oxidase 8 and superoxide dismutase (SOD). 9 Interestingly, it has been demonstrated that prion protein displays an SOD-like activity, which is abolished by deletion of the octapeptide-repeat region of prion protein. 10 Thus, copper homeostasis requires a fine tuning; at present, the regulation of the copper transport into and through the cell is poorly understood. In this context, we propose that PrP C is a putative candidate that it can modulate the copper availability, mainly in the central nervous system and thus modulating copper effects. The link between PrP C and copper came from early studies with cuprizone, a copper-chelating agent, which induces some neuropathological changes in mice similar to those found in prion diseases. 11, 12 Recent data support the notion that PrP C is involved in copper homeostasis mainly because of the presence of copperbinding sites in the N-terminus of the PrP C , [13] [14] [15] [16] [17] [18] the ability of this region to reduce copper, 4 the copperdependent endocytosis of PrP C from the cell surface, 19, 20 the altered copper metabolism and deficiencies present in synaptosomal fractions of PrP C knockout mice, 13 and the high sensitivity to copper toxicity and oxidative stress of cerebellar cells obtained from mice deficient in PrP C . 13 Copperbinding domains of PrP C are localized at the Nterminal region of the protein and are formed by four octarepeats in tandem (PrP 59-91 ). 13, 15, 18 Since PrP C is able to bind and reduce copper, we considered of interest to study whether the interaction of one or all the four N-terminal octapeptides of human PrP C with copper could prevent the effects of the metal in the brain.
To ascertain this hypothesis, we have used the intrahippocampal injection procedure and the evaluation of the spatial memory acquisition by the Morris water maze task. We found that PrP 59-91 protects against copper neurotoxicity, both at the behavioral and morphological levels. Moreover, the injection of the prion peptide alone induced toxicity, probably by reducing endogenous copper, which supports the essential role of copper in the normal brain function. Our results indicate that PrP C is one of the factors involved in brain copper homeostasis protecting hippocampal-dependent spatial learning paradigms from copper neurotoxicity. A preliminary account of this work was presented in the Eighth International Conference on Alzheimer's Disease and Related Disorders, that took place in Stockholm, Sweden. 21 
Materials and methods

Synthetic peptides
Surgical and injection protocol
Male Sprague-Dawley rats (300 g; 4 months old) were anesthetized with Equitesin (3.5 ml/kg. i.p.) and injected bilaterally into the dorsal hippocampus (À3.5 mm AP, 72.0 mm ML and -2.7 mm DV, according to Bregma) stereotaxically with a 10 ml Hamilton syringe with 27-gauge stainless steel. The animals were injected bilaterally with 3 ml (at rate of 0.5 ml/ min) of 0.5, 1, 2, 3 and 5 mM CuCl 2 , in the presence or absence of prion peptides; aCSF was used as vehicle. After 4 days, rats were trained in the Morris water maze for 2 weeks and the performance of the different groups was recorded for analysis. After training, the animals were fixed by intraheart perfusion to carry out histochemical procedures.
Behavioral test
All animals were trained in a circular water maze (1.6 m diameter and 75 cm deep, painted black) 22 using a two-trial per day regimen. The platform (9 cm diameter) always resided in the center of northwest quadrant (hidden platform quadrant). Water (50 cm deep) was maintained at 19-211C. Data were gathered with a video tracking system for water maze (HVS Imagem, Hampton, UK). Briefly, rats were trained with two trials a day, for 5 consecutive days, followed by 2 days off, and then trained for 5 additional days. Each trial began when rats were allowed to swim. A trial continued until the animal was put onto the platform for 5 s and returned to its cage. Upon completion of both the trials, the rats were removed from the maze, dried and returned to their cages.
Perfusion and fixation
Animals were deeply anesthetized with Equitesin (3.5 ml/kg. i.p.). Rats were perfused through the heart with saline (0.9% NaCl) followed by fixation with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). Brains were removed from their skulls and postfixed in the same fixative for 3 h at room temperature, followed by 20% sucrose in PBS at 41C overnight. After fixation, brains were coded to ensure unbiased processing and analysis. The brains were then cut into 40 mm coronal sections with a cryostat (Leitz Â 1900) at À201C, from Bregma À1.8 mm to Bregma À4.8 mm. 23 Sections from the same brain were divided in groups for analysis by the following procedures: Nissl staining (0.3% cresyl violet) and immunohistochemical staining of glial fibrillary acidic protein (GFAP).
Immunohistochemical staining
Free-floating immunohistochemical procedure was performed as previously described. 24 . Washing and dilution of immunoreagents were performed with 0.01 M PBS with 0.2% Triton X-100 (PBS þ T) throughout the experiments, and two PBS þ T washes were performed between every antibody incubation. Sections were pretreated with 0.5% H 2 O 2 for 30 min to reduce endogenous peroxidase activity followed by treatment with 5% normal goat serum (DAKO) at room temperature for 1 h to avoid nonspecific binding. GFAP detection was performed using rabbit anti-GFAP (1 : 500) polyclonal antibody incubated overnight at 41C. A horseradish peroxidase (HRP)-con-jugated goat anti-rabbit IgG second antibody (1:600) was used in GFAP detection incubated for 1 h at room temperature. The staining was developed by incubation for 15 min with 0.6% diaminobenzidine followed by addition of H 2 O 2 (0.01% final concentration) and incubation for 4 min. After immunostaining, all sections were mounted on gelatin-coated slides, airdried, dehydrated by serial rinses in graded ethanol solutions, cleared with xylene and cover-slipped with Canada balsam (Merck, Darmstadt, Germany).
Nissl staining
Mounted sections were defatted in xylene and hydrated in ethyl alcohol and water series. Nissl staining (cresyl violet) was performed as previously described. 24 
Image analysis
The number of both neuronal cells and GFAP-positive astrocytes in the upper leaf of the dentate gyrus was calculated in Â 40 pictures of coronal brain sections stained with Nissl or anti-GFAP antibody, using the SigmaScan Pro software. Likewise, the GFAP intensity in the astrocyte soma and the area of the astrocyte perikaryon were measured.
Statistical analysis
Results were expressed as mean 7 standard error. Two-way ANOVA was also conducted for analyzing data of the water maze. Student's t-test was carried out for the image analysis. Po0.05 was regarded as statistically significant.
Results
Intrahippocampal CuCl 2 injection induces spatial memory impairment, neuronal cell loss and astrogliosis We evaluated the effect of copper injection in the rat hippocampus, both at the behavioral and histological levels. Intrahippocampal injection of increasing CuCl 2 concentrations induced impairment in the spatial learning evaluated by Morris water maze performance (Figure 1a , b). Rats injected with 5 mM CuCl 2 showed the highest escape latency values (85 s at day 3 of training), while those injected with 0.5 mM CuCl 2 showed the lowest escape latency scores (30 s at day 3 of training). The behavioral impairment was not the result of a motor alteration, as evidenced by the similar swimming speed scores of both copper treated and control rats along the spatial training ( Figure 1c ). Representative swimming paths at day 8 of training are shown in Figure 1d . As observed, the deleterious effect of the increasing copper concentrations on the hippocampal-dependent spatial memory acquisition is clear.
The analysis of the hippocampal morphology showed that copper chloride injection caused neuronal cell loss in the dentate gyrus (DG), evidenced by the thinning of the upper leaf of this hippocampal region ( Figure 2 ). The extension of the neuronal damage was dependent on the copper concentration injected; thus, 3 and 5 mM CuCl 2 induced higher extensions of tissue damage (Figure 2e, f) in contrast with rats injected with the lower copper concentrations, which showed a mild thinning of the upper leaf of the DG (Figure 2b-d) . This is in agreement with the behavioral data, which showed more acute spatial memory impairment in rats injected with high copper concentrations (see Figure 1a Figure 3a ). To rule out the possibility that copper chloride can enhance the immunoperoxidase staining, brain sections of animals injected with ibotenic acid were soaked in a 5 mM copper solution for 20 min (or in PBS as control), before the GFAP immunostaining procedure. As observed in Figure 3g , h, no differences between both treatments in the immunostaining were observed, indicating that the injection of copper did not induce any enhancement in the immunohistochemical reaction. Since 5 mM copper chloride induced an evident impairment at both the behavioral and morphological levels, this specific concentration was chosen for the experiments with the prion peptides. It has been reported that in the cerebrospinal fluid, copper concentrations in the range of 0.5-2.5 mM copper are found, whereas 15 mM is the copper concentration present in the synaptic cleft. 25 Therefore, the concentration of 5 mM copper selected for our studies is within the physiological concentration range.
PrP 59-91 protects spatial memory against copper neurotoxicity The ability of the N-terminal region of the human PrP C to bind copper atoms was used to evaluate whether PrP 59À91 peptide was able to prevent the behavioral impairment caused by intrahippocampal copper injection. We coinjected the octarepeat region of the human PrP C (PrP 59-91 ) with copper at two molar ratios, 2 : 1 and 1 : 1 (copper : prion peptide) ( Figure  4 ). When they were coinjected at the 2 : 1 molar ratio (5 mM copper plus 2.5 mM PrP 59-91 ), rats showed escape latency values between control animals and copper-injected animals, indicating a partial neuroprotection against copper-neurotoxicity. Just in the last 3 days of training (days 10, 11, 12), rats showed (Figure 4b ) behaved like control animals along the 2 weeks of training, in comparison with rats injected with 5 mM copper. Thus, the PrP 59-91 peptide in the same molar ratio with respect to copper totally protected against copper-induced neurotoxicity. As with the copper injection, the presence of prion peptides did not induce motor impairments as evidenced by the similar swimming speed scores of these groups of animals ( Figure 4c ). In Figure 4d are shown representative swimming paths at day 8 of training. The neuroprotective effect of the prion peptide against copper neurotoxicity is clear when both are injected in the rat hippocampus. Unexpectedly, the injection of the PrP 59-91 peptide alone induced some behavioral alterations.
PrP 59-91 diminishes neuronal cell loss and hypertrophic astrocytes induced by copper injection The improved behavior of rats injected with copper plus the PrP 59-91 peptide may be related to a protection of the hippocampal anatomical structure against copper neurotoxicity. The histological analysis of rat brains injected with copper plus PrP 59-91 showed a partial neuroprotection of hippocampal morphology ( Figure 5 ), evidenced by an increased thickening of the upper leaf of the DG (compare Figures 2e, f and 5a, b) . This suggests that the improvement on the spatial memory performance is related to the protection of the normal hippocampal morphology, mainly at the level of the DG. This effect on neuronal survival can be observed in the graph of cell numbers (Figure 5e The analysis of the astrogliosis showed that the injection of copper plus PrP 59-91 reduced the glial reaction around the injection site induced by copper, in comparison with the metal injection alone (compare Figures 6a, b and 3e, f) and even in comparison with the prion fragment injection alone (Figure 6c, d) . These results suggest that the N-terminal octapeptide of human PrP C can prevent, at least partially, the strong astrogliosis induced by copper injection. To characterize the reactive astrocytes present around the injection site, a deeper analysis was carried out. Pictures (magnified Â 40) of brain sections stained with GFAP antibody were analyzed with SigmaScan Pro software (Figure 6e-j) , which allowed us to measure the density of reactive astrocytes, the intensity of GFAP staining in the soma and the area of the astrocyte pericaryon. As observed in the graphs, in addition to an increased density of reactive astrocytes induced by copper (Figrue 6k), the metal injection also induced the appearance of hypertrophic astrocytes, characterized by an enhanced intensity of the GFAP staining in the soma ( Figure  6l ) and an increased area of the astrocyte pericaryon (Figure 6m ). In contrast, the PrP 59-91 peptide was able to reduce the proliferation of astrocytes and reduce the astrocyte hypertrophic signals triggered by copper.
Molecular dissection of the protecting effect of PrP 59-91
peptide on spatial memory and neuropathological changes It has been previously shown that the N-terminal octapeptide of human PrP C is able to bind and reduce copper. 4, 6 . To elucidate which of these two actions were responsible for the protecting effect of the prion peptide, we used the PrP 59-91 peptide lacking either the copper-binding residues (PrP 59-91 H-A) or the reducing residues (PrP 59-91 W-A). 4 Rats injected with copper plus PrP 59-91 H-A showed a clear protection of spatial memory (Figure 7a) , as did the rats injected with copper plus the wild-type prion peptide. This indicates that the binding ability of the N-terminal octapeptide of human PrP C is not involved in the neuroprotection observed. However, rats injected with copper plus PrP 59-91 W-A showed almost no neuroprotection of the spatial memory, showing high escape latency values, with respect to control animals ( Figure 7b ). To visualize these results with a more sensitive parameter, the spatial acuity was calculated and plotted vs the escape latency ( Figure 7c ). As observed in the graph, control rats and those injected with copper plus PrP 59-91 H-A are located in a region of the graph with high spatial acuity values and low escape latency values. In contrast, rats injected with copper plus PrP 59-91 W-A are located in a graph position with lower values of spatial acuity, which is in agreement with the result presented in the previous figures. These results indicate that copper reduction is an important event in the neuroprotective effects of PrP 59-91 . Representative swimming paths are shown in Figure 7d , supporting the results obtained. We can also observe that the PrP 59-91 peptide lacking Trp residues lost its detrimental action, in contrast with the prion peptide lacking the His residues, suggesting that the reducing capacity of the prion peptide is related to its neurotoxic effect.
Analysis of the hippocampal morphology of brain sections of rats injected with copper plus PrP 59-91 H-A did not show important neuronal cell loss in the upper leaf of the DG (Figure 8a ). This indicates that this peptide was able to avoid the extensive neuronal cell loss caused by copper. In contrast, it was observed that the injection of copper plus (Figure 9i-k) . In addition, it is observed that the PrP 59-91 W-A peptide did not trigger astrocyte hypertrophic signals, in comparison with the PrP 59-91 H-A peptide. These results confirm the notion that the deleterious effect of the prion peptide is related to its copper-reducing ability.
In addition, we evaluated the neuroprotective effect of just one octamer of the prion fragment (PrP octa ). We observed that PrP octa was able to protect against copper neurotoxicity at the behavioral level in similar fashion to the wild-type prion peptide (Figure 10a) . Swimming paths at day 8 of training show clearly the neuroprotective effect of PrP octa against copperinduced neurotoxicity in the Morris water maze performance (Figure 10b) . Moreover, rats injected with copper plus PrP octa showed a normal morphology of the upper leaf of the DG (Figure 11a ) similar to that observed in rats injected with PrP octa alone (Figure 11b) , not showing neuronal cell loss ( Figure  11c) . A basal GFAP immunostaining was observed in animals injected with PrP octa in the absence or presence of copper (Figure 11d , e) and when Â 40 pictures were analyzed exhaustively (Figure 11f, g ), just a difference in the GFAP staining intensity in the astrocyte soma was obtained (Figure 11h ).
Discussion
The physiological function of PrP is unknown. In the last years, several studies have suggested that PrP C may play a role in copper homeostasis, [4] [5] [6] 19 and this action can lead to a modulation of copper effects. In this context, we have brought new evidences to support this notion, and suggest that the N-terminal octapeptide region of human PrP C may play a crucial role in modulating the copper actions in the central nervous system. In fact, the prion peptide is able to prevent and reverse the inhibitory action of copper on the conductance of the P2X 4 receptor, as reported by us recently. 26 This suggests that the human prion protein could act as a copper target in synapses modifying brain excitability through changes in conductance of neurotransmitter receptors sensitive to trace metal modulation. We evaluated if PrP 59-91 modulates copper effects in vivo. In this model, the N-terminal octapeptide of human PrP C was coinjected with copper into the rat hippocampus, expecting that the peptide would be able to decrease the toxicity induced by copper. This toxicity was probably induced by a local increment of Cu 2 þ generating free radicals, followed by Cu 2 þ binding and/or reduction by PrP C . The intrahippocampal injection effects were evaluated by analyzing the morphology of the injection site and the spatial learning acquisition using the Morris water maze task. It was observed that intrahippocampal injection of copper chloride induced an important impairment in the spatial learning, a behavioral parameter that was related to the histological alterations, including neuronal cell loss and gliosis around the injection site, in a concentration-dependent manner. When copper was coinjected with the N-terminal octapeptide of human PrP C , an important protection of spatial learning acquisition was observed along the 2 weeks of training, suggesting that PrP 59-91 is modulating the effects that copper induced in the hippocampal neurons.
In order to evaluate the role played by the binding and reduction of copper activities in the neuroprotection observed, we used the same PrP 59-91 peptide, but without His or Trp residues. The coinjection of copper with PrP 59-91 H-A shows a similar protection have reported that the expression of a prion protein in human neuroblastoma cells with a tethered N-terminal region to the membrane by an uncleaved signal peptide, compromises the cellular response to oxidative stress of these cells, which are more susceptible to hydrogen peroxide-and copper-induced toxicity. In accordance with this, a link between prion protein, copper binding and resistance to oxidative stress has been published. 30 Taking into account the fact that the different neuroprotective effects of the PrP 59-91 peptide lack either binding or reducing residues, it is possible that PrP 59-91 -induced toxicity observed in some control experiments would be related to the copper-reducing activity, because PrP 59-91 W-A injected alone did not induce such neurotoxicity. Thus, the wild-type PrP 59-91 and the variant PrP 59-91 H-A peptides, which contains the Trp residues, could act as copperreducing peptides, reducing endogenous copper or copper atoms belonging to other proteins with their consequent inactivation and triggering neuronal cell death signals. An interesting point is how the PrP 59-91 H-A peptide, which does not bind copper, is able to reduce the metal. It has been reported that glycine is able to coordinate copper via its amino and carboxylate group. Even the authors conclude that the affinity of copper for the prion octarepeat is less strong than that of copper for glycine. 31 Interestingly, the octarepeat region of prion protein has four glycine residues per octamer (PHGGGWGQ), which probably participates directly in the binding of copper atoms, which allows its reduction.
The optimal copper concentration, which can directly affect synaptic activity or the loss of function of several copper-containing proteins, may be altered in the presence of the prion peptides, which could explain the toxicity observed with the prion peptide alone. For example, PrP 59-91 can bind or reduce the copper present in the Cu/Zn-SOD1, altering the normal function of this enzyme, which has a highly protective effect against neuronal cell injury and edema formation as well as reperfusion injury after cerebral ischemia. [32] [33] [34] All of these observations strongly support the essential role that copper plays in the normal brain function.
In conclusion, our data indicate that the N-terminal octapeptide of human PrP C can modulate copper effects in vivo, supporting the notion that the prion protein is involved in copper actions in the mammalian central nervous system.
